Current Fungal Infection Reports最新文献_第10页

Skin Infections Caused by Emerging Candida Species 新出现的念珠菌引起的皮肤感染

IF 1.4

Current Fungal Infection Reports Pub Date : 2020-03-27 DOI: 10.1007/s12281-020-00380-9

V. M. Espinosa-Hernández, Verónica Morales-Pineda, E. Martínez-Herrera

引用次数: 5

Coccidioidomycosis in Children and Adolescents: an Update 儿童和青少年球虫病的最新进展

IF 1.4

Current Fungal Infection Reports Pub Date : 2020-03-12 DOI: 10.1007/s12281-020-00381-8

M. Maza-Morales, M. Rivas-Calderón, E. Barrón-Calvillo, M. García-Romero

引用次数: 2

Extrapolating Antifungal Animal Data to Humans - Is it reliable? 将抗真菌动物数据推断给人类--可靠吗？

IF 1.4

Current Fungal Infection Reports Pub Date : 2020-03-01 Epub Date: 2020-01-16 DOI: 10.1007/s12281-020-00370-x

Victoria M Stevens, Scott W Mueller, Paul M Reynolds, Robert MacLaren, Tyree H Kiser

{"title":"Extrapolating Antifungal Animal Data to Humans - Is it reliable?","authors":"Victoria M Stevens, Scott W Mueller, Paul M Reynolds, Robert MacLaren, Tyree H Kiser","doi":"10.1007/s12281-020-00370-x","DOIUrl":"10.1007/s12281-020-00370-x","url":null,"abstract":"Purpose of review: This article aimed to review animal models of antifungals and identifies human literature to assess if the extrapolation of results is reliable.Recent findings: Animal studies have helped identify AUC/MIC targets for new drugs and formulations such as isavuconazole and delayed release posaconazole that have translated to successful outcomes in humans. Models have also been influential in the identification of possible combination therapies for the treatment of aspergillosis, such as voriconazole and echinocandins. However, challenges are endured with animal models when it comes to replicating the pharmacokinetics of humans which has been exemplified with the newest itraconazole formulation. Additionally, animal models have displayed a survival benefit with the use of iron chelators and amphotericin for mucormycosis which was not demonstrated in humans.Summary: Animal models have been a staple in the development and optimization of antifungal agents. They afford the ability to investigate uncommon diseases, such as invasive fungal infections, that would otherwise take years and many resources to complete. Although there are many benefits of animal models there are also shortcomings. This is why the reliability of extrapolating data from animal models to humans is often scrutinized.","PeriodicalId":10813,"journal":{"name":"Current Fungal Infection Reports","volume":"14 1","pages":"50-62"},"PeriodicalIF":1.4,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083583/pdf/nihms-1550064.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37762142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Applying Pharmacogenomics to Antifungal Selection and Dosing: Are We There Yet? 将药物基因组学应用于抗真菌选择和给药:我们做到了吗?

IF 1.4

Current Fungal Infection Reports Pub Date : 2020-03-01 Epub Date: 2020-01-16 DOI: 10.1007/s12281-020-00371-w

Matthew A Miller, Yee Ming Lee

{"title":"Applying Pharmacogenomics to Antifungal Selection and Dosing: Are We There Yet?","authors":"Matthew A Miller, Yee Ming Lee","doi":"10.1007/s12281-020-00371-w","DOIUrl":"https://doi.org/10.1007/s12281-020-00371-w","url":null,"abstract":"Purpose of review: This review summarizes recent literature for applying pharmacogenomics to antifungal selection and dosing, providing an approach to implementing antifungal pharmacogenomics in clinical practice.Recent findings: The Clinical Pharmacogenetics Implementation Consortium published guidelines on CYP2C19 and voriconazole, with recommendations to use alternative antifungals or adjust voriconazole dose with close therapeutic drug monitoring (TDM). Recent studies demonstrate an association between CYP2C19 phenotype and voriconazole levels, clinical outcomes, and adverse events. Additionally, CYP2C19-guided preemptive dose adjustment demonstrated benefit in two prospective studies for prophylaxis. Pharmacokinetic-pharmacodynamic modeling studies have generated proposed voriconazole treatment doses based on CYP2C19 phenotypes, with further validation studies needed.Summary: Sufficient evidence is available for implementing CYP2C19-guided voriconazole selection and dosing among select patients at risk for invasive fungal infections. The institution needs appropriate infrastructure for pharmacogenomic testing, integration of results in the clinical decision process, with TDM confirmation of goal trough achievement, to integrate antifungal pharmacogenomics into routine clinical care.","PeriodicalId":10813,"journal":{"name":"Current Fungal Infection Reports","volume":"14 1","pages":"63-75"},"PeriodicalIF":1.4,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12281-020-00371-w","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37808133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Should Etest MICs for Yeasts Be Categorized by Reference (BPs/ECVs) or by Etest (ECVs) Cutoffs as Determinants of Emerging Resistance? 酵母的测试mic是否应按参考值(bp / ecv)分类，还是按测试值(ecv)截止值作为新出现耐药性的决定因素进行分类?

IF 1.4

Current Fungal Infection Reports Pub Date : 2020-02-20 DOI: 10.1007/s12281-020-00378-3

A. Espinel-Ingroff, E. Dannaoui

引用次数: 4

Molecular Characterization of Coccidioides spp. Strains Isolated from Patients in the Argentine Republic 从阿根廷共和国患者身上分离的球虫菌株的分子特征

IF 1.4

Current Fungal Infection Reports Pub Date : 2020-02-04 DOI: 10.1007/s12281-020-00372-9

A. Motter, M. C. López-Joffre, A. Toranzo, D. Salas, M. Viale, Flavia Vivot, A. Hevia, R. Abrantes, Julián Fernández, C. Canteros, R. Suárez-Alvarez

引用次数: 0

Diagnosis, Burden and Mortality of Pneumocystis jirovecii Pneumonia in Venezuela 委内瑞拉乙氏肺囊虫肺炎的诊断、负担和死亡率

IF 1.4

Current Fungal Infection Reports Pub Date : 2020-01-31 DOI: 10.1007/s12281-020-00377-4

M. Panizo, G. Ferrara, N. Garcia, Xiomara Moreno, T. Navas, E. Calderón

引用次数: 0

Could Fungicides Lead to Azole Drug Resistance in a Cross-Resistance Manner among Environmental Cryptococcus Strains? 杀菌剂是否会导致环境隐球菌交叉耐药?

IF 1.4

Current Fungal Infection Reports Pub Date : 2020-01-30 DOI: 10.1007/s12281-020-00373-8

J. P. F. Takahashi, L. M. Feliciano, D. Santos, S. Ramos, R. A. Oliveira, D. Attili-Angelis, Nadia Regina Rodrigues, J. Sampaio, M. dos Anjos Martins, M. Melhem

引用次数: 7

Nucleic Acid Tools for Invasive Fungal Disease Diagnosis 用于侵袭性真菌疾病诊断的核酸工具

IF 1.4

Current Fungal Infection Reports Pub Date : 2020-01-21 DOI: 10.1007/s12281-020-00374-7

P. White, A. Alanio, M. Cruciani, R. Gorton, L. Millon, V. Rickerts, R. Barnes, J. Donnelly, J. Loeffler

引用次数: 11

An Approach to Suspected Invasive Fungal Infection in Patients with Hematologic Malignancy and HCT Recipients with Persistent Neutropenic Fever Despite Mold-Active Prophylaxis 血液恶性肿瘤患者和HCT接受者持续中性粒细胞减少热疑似侵袭性真菌感染的方法，尽管有霉菌活性预防

IF 1.4

Current Fungal Infection Reports Pub Date : 2020-01-21 DOI: 10.1007/s12281-020-00375-6

Erica J. Stohs, A. Zimmer

引用次数: 5